03
May
2023
17:30
BST
12:30
EST
17:30
CET
Webinar
Video Hyperkalaemia in Cardiorenal Disease – A Case Based Discussion
-
Views:
11800
-
Likes:
42
Overview
Watch this engaging educational roundtable discussion 'Hyperkalaemia in Cardiorenal Disease – A Case Based Discussion', moderated by Prof James Burton (University of Leicester, UK). A renowned international faculty will explore emerging data and the changing landscape of medical management of hyperkalaemia.
RAASi therapy serves part of the foundational treatment for heart failure and chronic kidney disease, but it is also a risk factor for hyperkalaemia. This conundrum poses challenges to physicians managing cardio-renal patients.
To understand these challenges, we would like to canvass your current approach to hyperkalaemia management across several areas; these will form the basis of a unique, interactive educational event.
Take Part in Our Patient Case Studies
To understand these challenges, we would like to canvass your current approach to hyperkalaemia management across several areas; these will form the basis of a unique, interactive educational event. Take part in the two case studies below by watching and voting on the poll.
This programme is supported by an unrestricted educational grant from AstraZeneca.
Faculty:
![Shelley Zieroth](https://assets.radcliffecardiology.com/s3fs-public/author/2020-12/Zieroth-a-espace.png)
Shelley Zieroth
![Clara Bonanad Lozano](https://assets.radcliffecardiology.com/s3fs-public/author/2023-04/Clara%20Bonanad%20Lozano%20%20%281%29%20%281%29.png?VersionId=D46PN53knj4ohFh0t9EEZybOu3WNMkHx)
Clara Bonanad Lozano
![Andrew Frankel](https://assets.radcliffecardiology.com/s3fs-public/author/2021-02/Screenshot%202021-02-19%20at%2014.19.31.png)
Andrew Frankel
![James Burton](https://assets.radcliffecardiology.com/s3fs-public/author/2022-11/Screenshot%202022-11-15%20120029.png?VersionId=lyLygep2hgx9PUHo73fp6LTpVDftep8u)
James Burton
Agenda
Learning Objectives
The learning objectives of this programme are:
- Explain the relationship between sub-optimal RAASi therapy and poor cardio-renal outcomes
- Identify patients who would benefit from anti-hyperkalaemia medications
- Select appropriate anti-hyperkalaemia treatments across a range of patient profiles
- Adopt anti-hyperkalaemia medications as an approach to prolong optimal RAASi therapy
- Summarise current guideline recommendations on the use of potassium binding agents
Target Audience
This programme is aimed at a global target audience of
- Nephrologists
- Cardiologists
- Heart Failure Specialists
- Nurses
- GPs
- Pharmacists
- Primary Care Practitioners
- HCPs
Faculty Biographies
![Shelley Zieroth](https://assets.radcliffecardiology.com/s3fs-public/author/2020-12/Zieroth-a-espace.png)
Shelley Zieroth
Dr Shelley Zieroth is Professor at the College of Medicine, Max Rady Faculty of Health Sciences, University of Manitoba, as well as Director of the Heart Failure and Heart Transplant Clinics at St Boniface Hospital in Winnipeg, Canada. She is also Head of the Medical Heart Failure Program for Cardiac Sciences Manitoba.
She is involved in several heart failure clinical trials as a PI, National Lead or Executive Committee member. She is the Past President of the Canadian Heart Failure Society and Co-Chair of the Canadian Cardiovascular Society Heart Failure Guidelines. She is co-chair of Canada’s largest annual heart failure meeting, HF Update, and Past President of the Federation of Medical Women of Canada.
Dr Shelley Zieroth is an Editorial Board member of Cardiac Failure Review.
![Clara Bonanad Lozano](https://assets.radcliffecardiology.com/s3fs-public/author/2023-04/Clara%20Bonanad%20Lozano%20%20%281%29%20%281%29.png?VersionId=D46PN53knj4ohFh0t9EEZybOu3WNMkHx)
Clara Bonanad Lozano
Dr Clara Bonanad Lozano is a cardiologist at the University Clinical Hospital of Valencia, ES and president of the Association of Geriatric Cardiology of the Spanish Society of Cardiology. Her clinical interests are Myocardial Infarction, Echocardiography, Pacemakers, Cardiac Imaging, Diabetes, Cardiovascular, and Heart Failure.
![Andrew Frankel](https://assets.radcliffecardiology.com/s3fs-public/author/2021-02/Screenshot%202021-02-19%20at%2014.19.31.png)
Andrew Frankel
Dr Andrew Frankel has been working as a consultant nephrologist at Imperial College Healthcare NHS trust since 1995. He has experience in managing all aspects of kidney disease but has a particular interest in relation to the management of diabetes in the context of kidney disease. Over the years he has maintained a significant research interest in relation to diabetes and kidney, both in terms of how diabetes affects the kidneys leading to deterioration in kidney function, but also in relation to how the presence of kidney disease influences the management of diabetes. Because of this experience, Dr Frankel has played a significant role in the development of national guidelines on the management of diabetes in the context of kidney disease. He is a regular speaker both locally and nationally and indeed internationally in relation to matters pertaining to diabetes and the kidney.
In collaboration with colleagues within Imperial College and indeed both nationally and internationally, Dr Frankel has published research in relation to assessment of renal complications in patients with diabetes and obesity. He is active in clinical research and maintains a number of ongoing research studies.
Dr Frankel has significant commitment to and experience in relation to training the next generation of doctors, having been the director Imperial’s Foundation School from its inception to 2010, London lead for Foundation Training and Postgraduate Dean for south London from 2013 and 2018.
![James Burton](https://assets.radcliffecardiology.com/s3fs-public/author/2022-11/Screenshot%202022-11-15%20120029.png?VersionId=lyLygep2hgx9PUHo73fp6LTpVDftep8u)
James Burton
Prof James Burton is Honorary Consultant Nephrologist and Professor of Renal Medicine and Associate Dean for Clinical Research at the University of Leicester, Leicester, UK. His principal research interests are the mechanisms underlying uraemic cardiovascular disease modification of cardiovascular risk in patients with end-stage renal disease and the identification and application of novel biomarkers.
In addition Prof Burton is involved in the development and running of clinical trials; he is Chief Investigator for the NIHR funded NightLife trial investigating the impact of nocturnal dialysis on patient outcomes as well as the Kidney Research UK funded CONFIRM study exploring the utility of a novel cardiac magnetic resonance imaging (MRI) techniques in haemodialysis patients. Prof Burton is the independent Chair of two multi-centre NIHR Trial Steering Committees and sits on a number of others.
He is the current Chair of the UK Kidney Association Clinical Guidelines Committee and has himself chaired a number of UK guideline updates making sure that research translates into clinical practice.